Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
AHA 23: Screening for Peripartum Cardiomyopathies Using an AI Enanced Digital Stethoscope
Author(s): Demilade Adedinsewo Added: 1 year ago
AHA 23 - We are joined by Dr Demilade Adedinsewo (Mayo Clinic, US) to discuss the findings from a study investigating the effectiveness of an artificial intelligence-enabled ECG (AI-ECG) for cardiomyopathy detection in an obstetric population.In the intervention arm, the digital stethoscope correctly identified 92% of those with ejection fraction <50% and 100% of those with ejection fraction … View more

Demographic

Heart Failure
Research Area(s) / Expertise: Job title: Cardiologist
ProfPeter van der Meer is aCardiologist atUniversity Medical Centre Groningen, Groningen, NL. Profvan der Meer has a focus on heart failure and cardiac devices. He is a member of the ESC council of cardio-oncology, member of the working group on translational cardiology and peripartum cardiomyopathy of the ESC and associate editor of the European Journal of Heart Failure. View more
Job title: T32 Postdoctoral Researcher, Clinical Instructor of Medicine, Division of Cardiology
Agnes Koczo is a post-doctoral researcher and cardiologist at the University of Pittsburgh Medical Center. She completed both her residency and fellowship training with chief designation at the University of Pittsburgh and with special focus on women's health. Her fellowship and post-doctoral research focuses on a number of cardiovascular conditions that exclusively or disproportionately impact… View more
Mark Petrie
Research Area(s) / Expertise: Job title: Professor/Honorary Consultant (Institute of Cardiovascular & Medical Sciences)
Prof Mark Petrie is Professor of Cardiology in the Institute of Cardiovascular and Medical Sciences at the University of Glasgow, UK. Prof Petrie started his studies as an undergraduate at Edinburgh University, before training in cardiology in Glasgow. He worked as a heart failure and interventional cardiologist for many years before transferring to the University of Glasgow in 2016. Prof… View more
HFSA 25: The ATTRibute-CM Trial
Author(s): Ahmad Masri Added: 1 month ago
HFSA 2025 - Post hoc analysis of ATTRibute-CM reveals significant reduction in cardiovascular mortality and death after 30 months of acoramidis in patients with ATTR-CM.Dr Ahmad Masri (Oregon Health & Science University, US) joins us to discuss a post hoc exploratory analysis from the ATTRibute-CM trial examining the timing and magnitude of cardiovascular outcome reductions with acoramidis in… View more

Heart Failure
Emerging Therapies for Obstructive Hypertrophic Cardiomyopathy
Author(s): Emily Li-Wen Chu , Daniel Seung Kim , Ahmad Masri Added: 1 week ago

Heart Failure

Intervention
Diagnosing Hypertrophic Cardiomyopathy with Dr Sara Saberi
Author(s): Sara Saberi Added: 1 month ago
Master the diagnostic complexities of hypertrophic cardiomyopathy (HCM) with Dr Sara Saberi, a leading expert in inherited cardiovascular diseases.This comprehensive presentation, part of the Cardiomyopathies track of Women As One's CLIMB® 2025 Skills Training Program, provides essential insights into the nuanced approach required for accurate HCM diagnosis and risk stratification.Dr Saberi… View more

Heart Failure
Treatment of Hypertrophic Cardiomyopathy with Dr Tiku Owens
Author(s): Anjali T Owens Added: 1 month ago
Navigate the rapidly evolving treatment landscape for hypertrophic cardiomyopathy with Dr Anjali Tiku Owens, a renowned expert in inherited cardiovascular diseases and advanced heart failure.This comprehensive presentation, part of the Cardiomyopathies track of Women As One's CLIMB® 2025 Skills Training Program, explores both established and emerging therapeutic approaches for obstructive and non… View more

Heart Failure
Potential Reversibility of ATTR-CM through Anti-ATTR Amyloid Antibodies
Author(s): Marianna Fontana Added: 2 years ago
Prof Marianna Fontana (University College London, UK) joined us to discuss the discovery and impact of antibody-associated reversal of ATTR amyloidosis–related cardiomyopathy in three patients. Prof Fontana and her team, in a correspondence published in The New England Journal of Medicine, revealed the identification of an antibody linked to the spontaneous reversal of cardiac transthyretin… View more

Heart Failure
ESC 23: ATTRibute-CM Trial
Author(s): Julian Gillmore Added: 2 years ago
ESC 2023 — Prof Julian Gillmore (University College London, UK) joins us onsite to discuss the findings of the ATTRibute-CM Study (NCT03860935). ATTRibute-CM was a randomised double-blind trial which aimed to evaluate the safety and efficacy of acoramidis in a cohort of patients diagnosed with transtherytin amyloid cardiomyopathy (ATTR-CM). 632 patients were enrolled in the trial, and were… View more

Heart Failure